A Technical Guide to Raw Material Selection, Formulation, Capsule Filling and Quality Control
When a dietary supplement brand says, “We want to develop Alpha-GPC capsules providing 300 mg per serving,” the product target may appear clear. For a manufacturer responsible for formulation, raw-material sourcing and commercial production, however, 300 mg is only a product target—not a complete manufacturing specification.
Before confirming a quotation, sourcing the ingredient or finalizing capsule size and servings per bottle, several questions need to be answered. Does 300 mg refer to actual Alpha-GPC content or the total weight of the commercial raw material? Which commercial grade will be used? Is the assay reported on an as-is or dry basis? Does the material contain water, carriers or other components? Are its density, particle size and flow properties suitable for capsule production? Can the complete blend be mixed uniformly and filled consistently? Does the finished packaging provide adequate moisture protection?
These questions are connected. Raw-material specifications determine the input weight; input weight affects the total blend weight and volume; and powder properties influence blend uniformity, capsule filling and manufacturing consistency.
Developing a 300 mg Alpha-GPC capsule requires more than setting a label claim. It starts with understanding the actual quality attributes of the commercial ingredient. This article examines how assay calculations, raw-material evaluation and manufacturing verification affect commercial feasibility.
1. 300 mg Is the Product Target, Not the Raw-Material Input Weight
Alpha-GPC development begins by distinguishing three different quantities:
| Item | What it means |
| Target active content | The actual Alpha-GPC amount intended per serving |
| Commercial raw-material input | The ingredient weight calculated from its effective assay |
| Final capsule fill weight | The combined weight of the commercial ingredient, other actives and all excipients |
If the brand requires 300 mg of actual Alpha-GPC per serving, the raw-material input will not necessarily be 300 mg.
The theoretical calculation is:
M = T ÷ A
Where M is the commercial raw-material input, T is the target Alpha-GPC content, and A is the effective assay fraction on the relevant reporting basis.
| Effective raw-material assay | Theoretical input for 300 mg Alpha-GPC |
| 50% | 600 mg |
| 85% | 352.9 mg |
| 98% | 306.1 mg |
| 99% | 303.0 mg |
These are theoretical examples only. They do not imply that commercial materials at different assay levels have the same physical form or manufacturing suitability.
As-Is Assay vs. Dry-Basis Assay
A raw-material COA may report assay on an as-is basis or on a dry basis. These reporting bases must not be mixed.
For example, assume a batch has an Alpha-GPC assay of 98% on a dry basis and moisture of 1%. If the target is 300 mg of actual Alpha-GPC, the estimated as-is assay is:
98% × (1 − 1%) = 97.02%
The theoretical raw-material input is therefore:
300 ÷ 97.02% = 309.2 mg
If the COA already reports 98% on an as-is basis, moisture must not be deducted again. Final dispensing instructions must follow the approved analytical method, batch results, raw-material specification and the manufacturer’s dispensing procedure.
For a manufacturer, the assay value matters—but so does the basis and method used to determine it.
2. 50%, 85% and 98% Alpha-GPC: Assay Percentage Is Not the Whole Specification
Commercial Alpha-GPC materials can differ in assay, physical form, composition and manufacturing process. A grade should not be selected by comparing the percentage on a product name or sales sheet alone.
50% Alpha-GPC Commercial Material
At an effective assay of 50%, a theoretical 600 mg of raw material would be needed to provide 300 mg of Alpha-GPC. The remaining portion should not automatically be assumed to be a particular carrier. The supplier should identify all other components, including any maltodextrin or other carrier, water, excipients or stabilizing components.
85% Alpha-GPC Commercial Material
An 85% grade should not automatically be interpreted as a dry powder containing 85% Alpha-GPC. EFSA’s scientific assessment of a specific L-alpha-GPC novel food application describes materials in different physical forms, including a highly viscous, transparent GPC 85% material and a white to off-white crystalline powder identified as Alpha Size 100P. These materials should not be assumed to have the same capsule-processing characteristics.
98% High-Assay Alpha-GPC Powder
A higher-assay powder requires less theoretical raw-material input to reach the same active target. It may reduce the amount of active ingredient occupying the formulation and leave more room for other actives or excipients. However, a higher assay does not automatically mean better flow, lower moisture sensitivity or easier capsule filling.
| Evaluation point | 50% material | 85% material | 98% material |
| Theoretical input weight | Higher | Depends on assay basis | Lower |
| Carrier and other components | Confirm | Confirm | Confirm |
| Physical form | Confirm | Confirm | Confirm |
| Moisture | Test | Test | Test |
| Powder flow | Evaluate | Depends on physical form | Evaluate |
| Capsule suitability | Verify | Assess physical form | Verify |
Commercial ingredients should be compared by supplier, manufacturing site and specific material code—not by the assay percentage alone.
3. How Powder Density Affects Capsule Size and Capsules per Serving
After calculating the raw-material input, the next question is how much space the powder occupies. Capsule capacity depends not only on the capsule’s internal volume but also on the powder’s packing characteristics.
V = M ÷ ρb
Where V is theoretical powder volume, M is powder mass and ρb is bulk density. For a final blend weighing 500 mg:
| Bulk density | Theoretical volume |
| 0.40 g/mL | 1.25 mL |
| 0.50 g/mL | 1.00 mL |
| 0.60 g/mL | 0.83 mL |
| 0.70 g/mL | 0.71 mL |
These figures illustrate the relationship between density and volume. They are not HEKONA raw-material test results.
Bulk Density and Tapped Density
Bulk density is the mass per unit volume of a powder in its freely settled state. Tapped density is measured after a defined mechanical tapping procedure. The difference can help characterize how a powder packs under mechanical action, but neither value alone determines capsule-machine filling capability.
Capsule machines may use different dosing and filling principles, including dosator and tamping-pin systems. Their metering, compaction and fill performance can differ. A capsule-capacity chart is therefore not enough to guarantee that a formulation will fit a particular capsule size. The complete blend must be evaluated using its density, flow properties and the actual equipment configuration.
Capsule size is part of formulation design, but the final decision must be supported by filling trials.
4. Alpha-GPC Hygroscopicity: From Raw-Material Handling to Process Control
One important property to evaluate in Alpha-GPC is its hygroscopicity. A 2024 European Commission consultation document on the novel food status of L-alpha-GPC describes the material as strongly hygroscopic and notes that moisture absorption can cause it to become gel-like.
If the material is exposed to unsuitable temperature and humidity conditions, or is left unsealed after opening, potential issues may include moisture uptake, agglomeration, caking, changes in flow, adhesion to equipment surfaces, inconsistent feeding and variation in fill performance. These are risks to assess, not outcomes that should be assumed for every Alpha-GPC material.
Moisture-Control Considerations Across the Process
| Stage | Key considerations |
| Raw-material storage | Sealed packaging, storage conditions and batch status |
| Pre-production handling | Opening time, ambient temperature and relative humidity, exposure time |
| Blending and filling | Material transfer, caking, adhesion and equipment performance |
| Finished-product packaging | Barrier properties, seal integrity and desiccant suitability |
| Stability assessment | Moisture, assay, appearance, capsule condition and relevant quality attributes |
Environmental control limits should be established using supplier technical information, site risk assessment and manufacturing verification. A single humidity limit should not be applied indiscriminately to every Alpha-GPC material.
5. Blend Uniformity: Consistent Capsule Weight Does Not Guarantee Consistent Active Content
Consistent total capsule weight does not necessarily mean that every capsule contains the same amount of Alpha-GPC. If Alpha-GPC and other excipients differ substantially in particle size or density, segregation may occur during blending, transfer or equipment operation.
The result can be capsules with similar total fill weights but different proportions of Alpha-GPC in the blend, leading to variation in actual active content.
Powder Attributes That May Affect Blend Uniformity
- Particle size and distribution:Differences between ingredients can influence blending and material distribution.
- Powder density:Density differences may increase the risk of segregation.
- Particle morphology:Particle shape and surface characteristics can affect blending and flow.
- Flow and cohesion:Differences in flow can affect feeding, while cohesion may increase agglomeration and equipment residue.
How Should Blend Uniformity Be Evaluated?
Blend uniformity should not be assumed based only on blending time or mixer operation. Evaluation should consider the physical properties of ingredients and excipients, blending sequence and process, representative sampling locations, Alpha-GPC assay testing, and the risk of segregation during transfer and equipment operation.
| Quality measure | What it evaluates |
| Average Fill Weight | Average capsule fill weight |
| Fill Weight Variation | Differences in fill weight among capsules |
| Active Ingredient Content / Uniformity | Actual Alpha-GPC content and consistency per dosage unit |
A reliable capsule product needs both controlled fill weight and effective control of active-ingredient distribution.
For an overview of HEKONA’s laboratory equipment and testing capabilities, see Laboratory Testing Capabilities
6. From Samples to Commercial Production: Why Equipment Filling Trials Matter
The sample-development stage and commercial manufacturing stage answer different questions. Formulation samples help assess whether the formula and dosage form are feasible, whether appearance and preliminary fill weight meet the design, and whether obvious powder-processing issues are present. A small hand-filled sample does not prove commercial manufacturability.
Commercial equipment trials should assess the complete blend under the intended production conditions:
| Trial parameter | What to assess |
| Continuous feeding | Whether powder feeds consistently into the dosing system |
| Fill weight | Whether fill remains consistent over time |
| Blend condition | Whether caking, segregation or adhesion occurs |
| Equipment operation | Whether frequent adjustments are needed |
| Production speed | Filling performance at different operating speeds |
| Stop-and-restart behavior | Whether dosing changes after restarting |
| Material loss | Equipment residue and rejected units |
| Batch yield | Whether the predefined production target is met |
Capsule-filling machines differ in operating principles, dosing structures and powder requirements. A material that performs well on one machine may not behave identically on another.
HEKONA Capsule Manufacturing Capabilities: Capsule Manufacturing Capabilities
HEKONA’s capsule manufacturing page provides further information about its manufacturing processes and capabilities. Suitability for a specific project still needs to be assessed using the actual raw material and formulation.
7. Packaging and Stability: Maintaining Finished-Product Quality During Storage
For a hygroscopic ingredient, product development does not end when the capsules are filled. The finished product may still be affected by moisture and environmental conditions during packaging, transportation and storage.
Three levels should be distinguished: raw-material stability, stability of the final blend and capsule contents, and the moisture-protection performance of the finished packaging system. Raw-material stability data alone cannot establish the shelf life of the finished capsule product.
Packaging Factors to Evaluate
| Packaging factor | What to evaluate |
| Bottle material | Water-vapor barrier properties |
| Closure | Seal performance |
| Bottle-neck seal | Control of moisture exchange |
| Induction seal or liner | Integrity and sealing reliability |
| Desiccant | Capacity, quantity and suitability |
| Headspace | Air and moisture environment inside the bottle |
| Transportation | Temperature and humidity variations |
A desiccant cannot replace a properly designed and sealed packaging system. Its type and quantity should be evaluated against pack volume, initial product moisture, expected storage conditions and packaging performance.
Potential Stability-Study Parameters
| Parameter | Purpose |
| Alpha-GPC assay | Monitor active-content changes |
| Moisture or related indicators | Evaluate moisture changes |
| Appearance | Monitor color, caking and visible changes |
| Capsule-shell condition | Observe softening, deformation or brittleness |
| Disintegration | Evaluate dosage-form performance after storage |
| Microbiological attributes | Assess microbiological quality under specified storage conditions |
| Package integrity | Evaluate sealing and moisture protection |
The actual test panel should be based on product risk, target-market requirements and the product specification. Accelerated studies can help assess trends under elevated temperature and humidity, but should not be treated as direct proof of real-time shelf life without an appropriate scientific basis.
Finished-product shelf life should be supported by finished-product stability data, not inferred solely from the raw-material supplier’s stated shelf life.
8. Supplier Changes, Quality Control and Batch Traceability
A supplier change may affect more than purchasing cost; it can also affect manufacturing conditions. Even if two suppliers both label their material as 98%, they may differ in source, manufacturing process, analytical method, moisture, impurities, particle size, density or carrier composition.
Assessments Needed When Changing Raw-Material Suppliers
| Assessment stage | Work to complete |
| Supplier review | Manufacturer credentials, material source and supply capability |
| Specification review | Identity, assay, analytical method, moisture and impurities |
| COA review | Compare batch results with the approved specification |
| Formulation review | Recalculate effective content and input weight |
| Process review | Assess powder properties and manufacturing suitability |
| Verification review | Determine whether new trials are needed based on the change |
| Document control | Update specifications, supplier records and batch controls |
A traceable relationship should connect the approved supplier and material code, purchase lot and COA, incoming inspection and release, formula version and dispensing record, blending and filling records, finished-product testing, batch release and packaging records.
HEKONA Raw Material Sourcing and Supplier Qualification: Raw Material Sourcing and Supplier Qualification
For a deeper explanation of how supplier COAs differ from finished-product COAs during batch review, read: Supplier COA vs. Finished-Product COA
For brands planning long-term product supply, traceability between raw materials and finished-product batches is more meaningful than comparing purchase prices alone.
9. Confirm the Target Market Before Approving the Raw Material
The regulatory status of Alpha-GPC is not identical across all countries and regions. A material being marketed in the United States as a dietary-supplement ingredient does not automatically mean that it can be placed on the market in the European Union.
The European Commission’s Novel Food status consultation record dated 22 March 2024 identifies L-alpha-GPC as a Novel Food. The record states that a significant history of consumption in the EU before 15 May 1997 had not been demonstrated. This is a Novel Food status determination, not a market authorisation.
In 2026, EFSA issued a scientific opinion on a specific novel food application for L-alpha-GPC produced from soya phospholipids (lecithin). The application covered two forms: viscous liquid GPC 85% and the powder Alpha Size 100P. The proposed maximum use level in food supplements was 203.7 mg L-alpha-GPC per day, corresponding to 82.5 mg choline per day. EFSA concluded that the information submitted on the identity, production process, composition and amended specifications of this specific novel food did not raise safety concerns under the proposed conditions of use.
| Term | Meaning |
| Novel Food Status | Determines whether a food or ingredient falls within the Novel Food framework |
| EFSA Safety Assessment | Scientific evaluation of a specific application and proposed conditions of use |
| EU Novel Food Authorisation | Formal market authorisation under the applicable EU framework |
This EFSA opinion should not be read as a general safety endorsement of all Alpha-GPC materials, nor as confirmation that a daily intake of 300 mg has been assessed as safe by EFSA. A scientific opinion is also not an EU market authorisation. Under the European Commission’s authorisation procedure, a novel food may be lawfully placed on the EU market only after the Commission adopts an implementing act authorising it and updates the Union List.
As checked on 9 November 2026, the European Commission’s Novel Food status consultation register continues to list L-alpha-GPC (record dated 22 March 2024) as a Novel Food. L-alpha-GPC was not located in the Commission’s currently published Union List page. Brands planning to enter the EU market should recheck the latest application status, any adopted authorisation act and the Union List before placing a product on the market, and obtain a market-specific regulatory assessment for the exact source, manufacturing process, specification and proposed use level.
Target-market requirements should be considered before raw-material approval and formula finalization—not treated as a final administrative step.
10. HEKONA Alpha-GPC 300 mg Capsules: From Product Target to Manufacturing Feasibility
HEKONA’s existing Alpha-GPC 300 mg Capsules provide a practical example of this development approach.
| Product parameter | Current design |
| Target active content per serving | 300 mg Alpha-GPC |
| Capsules per serving | 2 vegetable capsules |
| Capsules per bottle | 60 |
| Servings per bottle | 30 |
| Commercial raw-material assay and input | Subject to the approved raw-material specification and batch COA |
HEKONA Alpha-GPC 300 mg Capsules – Product Details: View Product Details
The 300 mg figure represents the target active content per serving, not a confirmed commercial raw-material input weight. The actual input can only be finalized after the supplier, material specification and batch COA have been approved.
If a brand requests 300 mg per capsule or wants to use one capsule per serving, the project needs to reassess the raw-material assay, ingredient input, space required by other actives and excipients, blend density and flow, capsule size, equipment filling capability, blend uniformity, moisture-protective packaging and finished-product stability.
HEKONA’s formulation, sourcing, production and quality teams need to assess these factors together.
HEKONA Finished Product Quality Assurance: Finished Product Assurance and Batch Release
The manufacturer’s value is not simply purchasing Alpha-GPC and filling it into capsules. It is the ability to evaluate product targets, raw-material quality, formulation design, manufacturing processes and finished-product quality as one connected system.
11. Technical Information to Confirm Before Quotation
A commercial quotation for Alpha-GPC capsules should not be based only on 300 mg / 60 capsules / price per bottle. If the commercial raw-material specification, capsule count and manufacturing conditions are not confirmed, the quotation may need to change during development.
| Item | Information to confirm |
| Product target | Does 300 mg refer to active content or raw-material weight? |
| Commercial raw material | Supplier, manufacturing site and material code |
| Raw-material assay | 50%, 85%, 98% or another specification |
| Assay basis | As-is or dry basis |
| Material composition | Carriers, moisture and other components |
| Powder properties | Particle size, bulk density, tapped density and flow |
| Capsule size | Size 0, 00 or another size |
| Capsules per serving | One capsule, two capsules or another design |
| Other active ingredients | Whether a multi-ingredient formula is required |
| Packaging | Bottle, closure and moisture-protection requirements |
| Target market | United States, Europe or another market |
| Sample purpose | Formulation sample or commercial equipment trial |
| Stability requirement | Target shelf life and supporting data required |
If these parameters are not yet finalized, the manufacturer can provide a development-stage estimate. Assumptions about raw-material grade, formula and quotation conditions should be clearly documented.
12. Frequently Asked Questions
1. If the Alpha-GPC label states 300 mg, does manufacturing require only 300 mg of raw material?
Not necessarily. If 300 mg refers to actual Alpha-GPC and the commercial ingredient has an assay below 100%, the raw-material input will be higher. A 50% material theoretically requires 600 mg, while a 98% material theoretically requires approximately 306.1 mg. The final input must be calculated using the COA assay basis, moisture data and batch results.
2. Is 98% Alpha-GPC always better for capsules than a 50% material?
No. A 98% material reduces theoretical input weight, but powder density, hygroscopicity, particle size, flow, cohesion, equipment performance and cost must also be evaluated. Selection should be based on the complete product design rather than assay percentage alone.
3. Why are some 300 mg Alpha-GPC products supplied in one capsule and others in two?
The active amount per serving does not determine capsule count by itself. Commercial raw-material assay, excipient weight, other active ingredients, powder density, capsule volume and equipment filling capability all affect the design. NIH’s Dietary Supplement Label Database (DSLD), for example, records a Jarrow Formulas label showing 300 mg per capsule. An Evlution Nutrition label records 600 mg of 50% Alpha-GPC per two-capsule serving and presents the product as providing 300 mg Alpha-GPC per serving. These are label records only; they do not establish the actual batch assay or manufacturing process.
4. Can a desiccant alone solve Alpha-GPC moisture sensitivity?
No. A desiccant is only one part of a moisture-protection strategy. Raw-material exposure, manufacturing environment, blending and transfer, capsule filling and final package sealing can all affect moisture conditions. Moisture control should cover the full process and be supported by finished-product stability assessment.
5. Can a product move directly to bulk production after a successful hand-filled sample?
Not automatically. A hand-filled sample helps assess formulation, dosage form and appearance. Commercial production also requires evaluation of continuous feeding, blend uniformity, fill-weight consistency, equipment residue and production yield on the intended equipment.
6. Can the Alpha-GPC supplier be changed if the label remains the same?
Not without assessment. A new supplier may differ in assay basis, moisture, particle size, density, carriers and powder properties. The new specification should be reviewed, input weight recalculated and process changes assessed. Further equipment trials or stability work may be needed depending on the differences.
7. Can the same Alpha-GPC material be used for both the US and EU markets?
The ingredient name alone is not enough to determine this. The specific source, manufacturing process, regulatory status, product classification, conditions of use and labeling requirements must be checked for each target market. The European Commission’s 2024 status consultation lists L-alpha-GPC as a Novel Food. EFSA’s 2026 opinion relates to a specific soya-derived material and proposed use level of up to 203.7 mg/day; it is not a general confirmation for all materials or for a 300 mg/day intake. The latest EU authorisation acts and Union List should be checked before market entry.
Conclusion: Alpha-GPC 300 mg Is More Than a Label Claim—It Is a Manufacturing Engineering Question
Taking a 300 mg Alpha-GPC capsule from concept to commercial production involves more than sourcing an ingredient or filling capsules.
First, at the formulation and raw-material level, the manufacturer must establish actual active content, commercial assay, assay basis, carrier composition and the required raw-material input.
Second, at the powder and process level, the manufacturer must evaluate density, particle size, flow, hygroscopicity, blend uniformity, capsule volume and equipment filling performance.
Third, at the quality and stability level, the manufacturer needs appropriate raw-material qualification, batch testing, in-process controls, finished-product testing, moisture-protective packaging, stability assessment and batch traceability.
Together, these factors determine whether a development sample can be translated into a repeatable and controlled commercial product.
For a brand, selecting Alpha-GPC should not be a matter of choosing 98% over 50% or simply comparing supplier prices. The relevant question is whether the specific commercial ingredient can support the target active content, capsule configuration, formulation cost, manufacturing consistency, finished-product quality and target-market requirements.
For a manufacturer, professional value is not merely producing a bottle labeled 300 mg. It is the ability to explain the technical basis for formulation and manufacturing decisions and support the finished product with appropriate verification and quality records.
That is the complete path from an Alpha-GPC raw-material specification to commercial capsule manufacturing.
Discuss Your Alpha-GPC Project with HEKONA
If you are developing an Alpha-GPC supplement or reviewing an existing formula, HEKONA can help assess raw-material specifications, active-content targets, capsule design and commercial manufacturing feasibility.
Contact HEKONA to Discuss Your Project
References
Regulatory source check: 9 November 2026. Official registers and authorisation status may change; recheck before market placement.
NIH DSLD – Jarrow Formulas, Alpha GPC 300 mg (label record; serving size: 1 capsule): Open NIH DSLD record
NIH DSLD – Evlution Nutrition, Alpha GPC 300 mg (label record; 600 mg of 50% Alpha-GPC per 2-capsule serving): Open NIH DSLD record
European Commission (2024) – Consultation on the Novel Food Status of L-alpha-GPC (published 22 March 2024): Open official consultation record (PDF)
EFSA Journal (2026) – Safety of L-alpha-GPC from Soya Phospholipids (Lecithin), e10008: Read EFSA scientific opinion
European Commission – Consultation Process on Novel Food Status: View official consultation register
European Commission – Union List of Authorised Novel Foods: View current Union List
European Commission – Novel Food Authorisation Procedure: View authorisation procedure

